[go: up one dir, main page]

CL2014002181A1 - Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. - Google Patents

Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.

Info

Publication number
CL2014002181A1
CL2014002181A1 CL2014002181A CL2014002181A CL2014002181A1 CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1 CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A CL2014002181 A CL 2014002181A CL 2014002181 A1 CL2014002181 A1 CL 2014002181A1
Authority
CL
Chile
Prior art keywords
cancer
crystalline form
pyrazolopyrimidine
lymphoma
monohydrate
Prior art date
Application number
CL2014002181A
Other languages
English (en)
Inventor
Roushan Afroze
Indu T Bharathan
Jeffrey P Clavarri
Paul E Fleming
Jeffrey L Gaulin
Mario Girard
Steven P Langston
Francois R Soucy
Tzu-Tshin Wong
Yingshun Ye
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of CL2014002181A1 publication Critical patent/CL2014002181A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014002181A 2012-02-17 2014-08-14 Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma. CL2014002181A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17

Publications (1)

Publication Number Publication Date
CL2014002181A1 true CL2014002181A1 (es) 2014-12-12

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002181A CL2014002181A1 (es) 2012-02-17 2014-08-14 Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.

Country Status (30)

Country Link
US (4) US9290500B2 (es)
EP (3) EP3536692B1 (es)
JP (1) JP6122877B2 (es)
KR (1) KR20140123104A (es)
CN (1) CN104136399B (es)
AR (1) AR092797A1 (es)
BR (1) BR112014020365B1 (es)
CA (1) CA2864672C (es)
CL (1) CL2014002181A1 (es)
CO (1) CO7071135A2 (es)
CR (1) CR20140380A (es)
DO (1) DOP2014000187A (es)
EA (1) EA035020B1 (es)
EC (1) ECSP14019113A (es)
ES (1) ES2739150T3 (es)
GE (1) GEP201706687B (es)
HK (1) HK1201817A1 (es)
IL (1) IL234016A0 (es)
MA (1) MA35932B1 (es)
MX (1) MX352963B (es)
NZ (1) NZ628969A (es)
PE (1) PE20142244A1 (es)
PH (1) PH12014501832A1 (es)
SG (2) SG11201404757WA (es)
TN (1) TN2014000351A1 (es)
TW (1) TWI593688B (es)
UA (1) UA116534C2 (es)
UY (1) UY34629A (es)
WO (1) WO2013123169A1 (es)
ZA (1) ZA201406103B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
HK1201817A1 (en) 2012-02-17 2015-09-11 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EA032577B1 (ru) 2013-07-02 2019-06-28 Милленниум Фармасьютикалз, Инк. Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
US10335411B2 (en) 2014-10-29 2019-07-02 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and radiation
TW201625256A (zh) * 2014-10-29 2016-07-16 千禧製藥公司 泛素活化酶抑制劑及化療劑之投藥
CN112996790B (zh) 2018-10-30 2023-11-03 克洛诺斯生物公司 用于调节cdk9活性的化合物、组合物和方法
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213628A1 (en) 2002-02-28 2003-09-16 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2004026229A2 (en) 2002-09-04 2004-04-01 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7951810B2 (en) 2005-02-04 2011-05-31 Millennium Pharmaceuticals, Inc. Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
AR055206A1 (es) 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
DK1989206T3 (da) 2006-02-02 2012-10-08 Millennium Pharm Inc E1-aktiveringsenzymhæmmere
WO2007099021A1 (en) * 2006-02-28 2007-09-07 Sez Ag Device and method for liquid treating disc-like articles
KR101555258B1 (ko) * 2006-08-08 2015-09-24 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
WO2008154642A2 (en) 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
EP2540726B1 (en) * 2007-08-02 2019-10-09 Millennium Pharmaceuticals, Inc. Intermediates for the synthesis of E1 activity activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
US8809356B2 (en) 2011-08-24 2014-08-19 Millennium Pharmaceuticals, Inc. Inhibitors of NEDD8-activating enzyme
HK1201817A1 (en) 2012-02-17 2015-09-11 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EA032577B1 (ru) 2013-07-02 2019-06-28 Милленниум Фармасьютикалз, Инк. Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Also Published As

Publication number Publication date
EA035020B1 (ru) 2020-04-17
CR20140380A (es) 2014-10-28
US20160244455A1 (en) 2016-08-25
MX352963B (es) 2017-12-15
UA116534C2 (uk) 2018-04-10
ZA201406103B (en) 2017-11-29
ECSP14019113A (es) 2015-09-30
CA2864672C (en) 2018-01-09
SG10201606581RA (en) 2016-09-29
MA35932B1 (fr) 2014-12-01
JP6122877B2 (ja) 2017-04-26
CN104136399B (zh) 2018-08-07
US9290500B2 (en) 2016-03-22
DOP2014000187A (es) 2014-10-15
US20170217968A1 (en) 2017-08-03
BR112014020365B1 (pt) 2023-02-23
TW201345909A (zh) 2013-11-16
TWI593688B (zh) 2017-08-01
US20140088096A9 (en) 2014-03-27
ES2739150T3 (es) 2020-01-29
KR20140123104A (ko) 2014-10-21
AR092797A1 (es) 2015-05-06
US10202389B2 (en) 2019-02-12
EP3173413B1 (en) 2019-05-01
CA2864672A1 (en) 2013-08-22
EP3536692B1 (en) 2021-04-07
CN104136399A (zh) 2014-11-05
EP3173413A1 (en) 2017-05-31
WO2013123169A1 (en) 2013-08-22
US9796725B2 (en) 2017-10-24
EP2814791A1 (en) 2014-12-24
HK1201817A1 (en) 2015-09-11
SG11201404757WA (en) 2014-09-26
TN2014000351A1 (en) 2015-12-21
EP2814791A4 (en) 2015-08-19
CO7071135A2 (es) 2014-09-30
US20130217682A1 (en) 2013-08-22
MX2014009944A (es) 2014-11-10
NZ628969A (en) 2017-03-31
PH12014501832A1 (en) 2014-11-17
US9663525B2 (en) 2017-05-30
EP3536692A1 (en) 2019-09-11
PE20142244A1 (es) 2015-01-07
UY34629A (es) 2013-09-02
EA201400831A1 (ru) 2014-12-30
US20170369499A1 (en) 2017-12-28
JP2015508775A (ja) 2015-03-23
BR112014020365A2 (pt) 2020-12-22
GEP201706687B (en) 2017-06-26
IL234016A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
CL2014002181A1 (es) Entidad quimica derivada de pirazolopirimidina, inhibidora de la enzima activadora de ubiquitina; forma 1 cristalina anhidra; forma 2 cristalina monohidratada; composicion farmaceutica; metodo para tratar el cancer; y uso para el tratamiento de cancer de pulmones, cancer de ovarios, cancer de colon, cancer de mama o linfoma.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
HK1214815A1 (zh) Zeste增强子同源物2的抑制剂
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
EA201600622A1 (ru) Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
CL2015001250A1 (es) Compuestos derivados de triazolopirazinas, inhibidores de brd4; preparacion farmaceutica; y su uso en el tratamiento y/o la prevencion de cancer, tal como cancer de pulmon, higado, colon, cerebro, tiroides, mamas, entre otros.
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TN2015000516A1 (en) Chemical compounds
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
WO2013173441A3 (en) Enhancer of zeste homolog 2 inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
EA201400178A1 (ru) Лечение рака молочной железы
IL231835A0 (en) Pyrrolopyrimidine compounds for cancer treatment
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
MA40076A (fr) Inhibiteurs de syk
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2014000641A1 (es) Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
EP3133073A3 (en) Inhibitors of iap
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.